RE:RE:4 days WHIPPANY, N.J., Dec. 17, 2014 /PRNewswire/ -- Bayer HealthCare has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound
https://www.prnewswire.com/news-releases/bayer-submits-biologics-license-application-for-bay-81-8973-for-the-treatment-of-hemophilia-a-in-adults-and-children-300011070.html
WHIPPANY, N.J., March 4, 2015 /PRNewswire/ -- Bayer HealthCare today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for BAY 81-8973, a recombinant Factor VIII compound.
https://www.prnewswire.com/news-releases/fda-accepts-bayers-biologics-license-application-for-investigational-treatment-option-in-hemophilia-a-300045306.html
Hmm that seems closer to 74 days than 60...